**Abstract**

Background: Medullary thyroid carcinoma (MTC) is a rare type of thyroid cancer that occasionally occurs as part of MEN2A. The universal treatment of MTC is total thyroidectomy with central lymph node dissection. For disease progression, carcinoembryonic antigen (CEA) and calcitonin (CTN) need to be followed. Our aim was to study the presence and patterns of the above-mentioned characteristics of MTC in our population. Methodology: This retrospective study was conducted in a tertiary care hospital of Pakistan in which data of thirty-two medullary thyroid cancer patients over the past 20 years were reviewed and analysed after fulfillment of inclusion criteria. Their clinical, pathological, biochemical and treatment modalities were recorded through a retrospective review of their medical record files. Results: The mean age of patients was 42.88 ± 2.67 years in our study, with a male-to-female ratio of 2:1. Patients with sporadic MTC were 68.8%, while 31.2% were familial. The rates of metastasis were highest in bones followed by lungs and liver. Total thyroidectomy was performed in 26 (81.2%) patients and among those chemotherapy and XRT were performed in one and two patients, respectively. Histologically, the mean tumour size was 7.62 ± 3.64 cm. Median pre-surgery calcitonin was 5756 pg/ml that decreased to 29.3 pg/ml post-surgery. Median pre-surgery CEA level was 246.5 ng/ml that decreased to 6.39 ng/ml post-surgery. Two patients were RET positive. Conclusion: MTC usually presents in the fourth decade of life with male predominance and mostly sporadic occurrence. Total thyroidectomy with subsequent serial calcitonin and CEA levels thereafter are the mainstay of treatment and follow-up.

**Keywords:** Clinicopathological characteristics, developing country, medullary thyroid cancer

**INTRODUCTION**

Medullary thyroid carcinomas are rare tumours and account for 5%–8% of all thyroid carcinomas but represent up to 13.4% of thyroid cancer-related mortality.[1] These tumours are derived from the parafollicular C cells of the thyroid gland that produce calcitonin. 75–85% of the cases occur as sporadic, and another 20–25% occur as hereditary form caused by a mutation in RET proto-oncogene.[2] The hereditary form is associated with pheochromocytoma and hyperparathyroidism, and together they are labelled as multiple endocrine neoplasia (MEN2A).[3] MTC may present clinically as neck swelling of thyroid origin or lymphadenopathy. They may also cause local compressive symptoms in the form of dysphagia, hoarseness or stridor.[4,5]

In advanced cases, these tumours may present with metastatic lesions to the lungs, liver, bones and brain. Biochemically, these tumours produce calcitonin (CTN) and carcinoembryonic antigen (CEA), which are used for diagnosis and monitoring of disease progression. High levels of these markers may indicate advanced disease.[6] Total thyroidectomy with neck dissection is the treatment modality of choice, and the extent of neck dissection depends on the number of lymph nodes involved.[7] Post-operatively, patients are followed up with calcitonin and CEA levels at 3–6-month intervals. For metastatic lesions, MRI and CT scans may be considered.[8]

Patients with hereditary MTC are also screened for pheochromocytoma and hyperparathyroidism before the surgery. Patients with high levels of serum metanephrines and...
normetanephrines are optimized first with medical treatment to control blood pressure.[9]

There have been only a few studies to assess the clinical characteristics of this disease entity. Timely diagnosis can lead to earlier detection of cases and better therapeutic outcomes. Furthermore, family members can also be screened before they possibly develop the tumour. Hence, we plan to undertake this study so that the characteristics and treatment outcomes could be ascertained in our population.

**Materials and Methods**

This was a retrospective review of patient records presented to the tertiary care hospital in Karachi, Pakistan, for the diagnosis and management of medullary thyroid cancer. Inpatient and outpatient records were included. Demographic, clinical, laboratory data, information related to treatment pattern and follow-up for medullary thyroid cancer were recorded in pro forma.

Data were collected retrospectively by reviewing patient records for both baseline and subsequent visits post-intervention (surgery and medical therapy). For each patient, we analysed the following data recorded by the primary physician at the diagnosis of medullary thyroid cancer: age and sex, estimated duration since diagnosis, median serum calcitonin and CEA pre- and post-surgery, histopathology and treatment modalities. After the approval from the ethical review committee (ERC) of our centre, we requested the health information and management services (HIMS) to provide the list of patients diagnosed to have thyroid cancer.

A non-probability convenience sampling technique was used to recruit the study participants. A total of 32 patients fulfilled the diagnosis of medullary thyroid cancer based on the clinical characteristics and biochemical markers and were included in the study from 2000 to 2020. These patients were either undergoing treatment with surgery/medical therapy for MTC or being followed up in a tertiary care hospital in Karachi, Pakistan.

**Inclusion criteria**

The inclusion criteria included confirmed cases of medullary thyroid cancer fulfilling the clinical features and endocrine society diagnostic criteria:

1. Biochemically diagnosed cases of medullary thyroid cancer based on high serum CTN levels either with positive biopsy or with fine-needle aspiration, thyroid nodules and cervical lymphadenopathy, or distant metastases. The diagnosis was confirmed by surgical histological results.
2. Age ≥18 years, either sex.
3. MEN2A will be considered positive if at least one of the family members had a history of hyperparathyroidism or pheochromocytoma, alongside the presence of RET proto-oncogene mutation.

Similarly, MEN2B will be considered if one or more family members had morphological characteristics of the

**Table 1: Patients’ characteristics**

| Variables                      | Results     |
|--------------------------------|-------------|
| Age (years)                    | 42.88±2.67  |
| Gender                         |             |
| Male                           | 21 (65.6%)  |
| Female                         | 11 (34.4%)  |
| Duration of symptoms (years)   | 0.96±0.29   |
| Age at diagnosis (years)       | 39.84±2.76  |
| Sporadic or familial disease   |             |
| Sporadic                       | 22 (68.8%)  |
| Familial                       | 10 (31.2%)  |
| Familial disease diagnosis (Total=10 patients) |         |
| Familial disease diagnosed by symptoms | 6 (60%)    |
| Familial disease diagnosed by screening | 4 (40%)     |

**Table 2: Presenting complaints**

| Variables                      | Results     |
|--------------------------------|-------------|
| Clinical characteristics       |             |
| No neck swelling               | 6 (18.8%)   |
| Neck swelling                  | 26 (81.2%)  |
| History of prior thyroid surgery |          |
| No                             | 30 (93.8%)  |
| Yes                            | 2 (6.2%)    |
| Lymph nodes palpable           |             |
| Unknown                        | 13 (40.6%)  |
| Yes                            | 14 (43.8%)  |
| No                             | 5 (15.6%)   |
| Local metastasis               |             |
| None                           | 13 (40.6%)  |
| Unilateral lymph node          | 3 (9.4%)    |
| Bilateral lymph node           | 16 (50%)    |
| Distant metastasis             |             |
| None                           | 24 (75%)    |
| Lungs                          | 3 (9.4%)    |
| Liver                          | 1 (3.1%)    |
| Bone                           | 4 (12.5%)   |
| Metastasis in local structures or in more than two distant sites (other than lymph node) | |
| None                           | 25 (78.1%)  |
| Local structures               | 5 (15.6%)   |
| More than two distant sites    | 2 (6.2%)    |
| Local symptoms                 |             |
| None                           | 27 (84.4%)  |
| Hoarseness                     | 3 (9.4%)    |
| Dyspnoea                       | 1 (3.1%)    |
| Vocal cord paralysis           | 1 (3.1%)    |
| Systemic symptoms              |             |
| None                           | 30 (93.8%)  |
| Diarrhoea                      | 1 (3.1%)    |
| Other                          | 1 (3.1%)    |
| Family history                 |             |
| None                           | 22 (68.8%)  |
| MEN 2                          | 8 (25.0%)   |
| RET+                           | 1 (3.1%)    |
| Thyroid Ca                     | 1 (3.1%)    |
**Table 3: Staging of medullary thyroid cancer**

| Variables | Results |
|-----------|---------|
| Tumour size (cm) | 7.62±3.64 |
| TNM staging (invasion) | |
| No invasion to surrounding structures | 16 (50%) |
| Local invasion (positive) | 10 (31.2%) |
| Unknown | 6 (18.8%) |
| TNM staging (invasion focality) | |
| Unifocal | 16 (50%) |
| Bifocal | 7 (21.8%) |
| Multifocal | 3 (9.4%) |
| Not known | 6 (18.8%) |
| TNM staging (laterality) | |
| Unilateral | 14 (43.7%) |
| Bilateral | 12 (37.5%) |
| Not known | 6 (18.8%) |
| TNM staging (lymph node metastasis) | |
| No | 10 (31.2%) |
| Yes | 18 (56.3%) |
| Not known | 6 (18.8%) |
| TNM staging (distant metastasis) | |
| No | 21 (65.6%) |
| Yes | 8 (25.0%) |
| Not known | 3 (9.4%) |

**Table 4: Biochemical markers and FNAC**

| Variables | Results |
|-----------|---------|
| Calcitonin (median value) pg/ml | |
| Pre Surgery | 5756 |
| Post Surgery | 29.3 |
| CEA (median value) ng/ml | |
| Pre Surgery | 246.5 |
| Post Surgery | 6.39 |
| Hyperparathyroidism | |
| No | 30 (93.5%) |
| Yes | 2 (6.5%) |
| Pheochromocytoma | |
| No | 31 (96.9%) |
| Yes | 1 (3.1%) |
| TSH pre-surgery | 3.21±1.07 |
| Calcium pre-surgery | 9.12±0.18 |
| RET | |
| Positive | 2 (6.2%) |
| Not done/available | 30 |
| FNAC | |
| MTC | 12 (37.5%) |
| Malignant cell | 3 (9.4%) |
| Bethesda Category III | 2 (6.2%) |
| Not Performed | 15 (46.9%) |

**Statistical analysis**

All analyses were conducted by using the Statistical Package for Social Sciences (Release 19.0, standard version, copyright © SPSS; 1989-02). A descriptive analysis was performed. Proportions were calculated for categorical variables and mean SD for continuous ones.

**Results**

The mean age of patients with medullary thyroid carcinoma (MTC) was 42.88 ± 2.67 years in our study, with male to female ratio of 2:1. The other demographic features are shown in table 1.

81.2% of patients presented with neck swelling, lymph nodes were palpable in 43.8% of patients and distant metastasis were present in 25% of the patients. The rates of metastasis were highest in bones followed by lungs and liver (12.5%, 9.4%, and 3.1% respectively) [Table 2].

Histologically, the mean tumor size was $7.62 \pm 3.64$ cm with 8 (25%) patients having distant metastasis. Lymph node metastasis was present in 18 (56.3%) of the patients. 50% of carcinomas in our study were unifocal, followed by bifocal (21.8%) and multifocal (9.4%). The further details of staging of medullary thyroid cancer is mentioned in table 3.

The details of biochemical markers pre and post surgery and FNAC is shown in table 4.

Total thyroidectomy was done in 26 (81.2%) of the patients while one patient had subtotal thyroidectomy followed by complete thyroidectomy as initial fine needle aspiration cytology (FNAC) was Bethesda category 3. Surgery was not performed in 5 patients due to distant metastasis or palliative intent. Chemotherapy was given to only one patient while radiotherapy (XRT) was performed in two patients along with total thyroidectomy and lymph node dissection [Table 5].

**Discussion**

In our study, the mean age of patients with medullary thyroid carcinoma (MTC) was 42.88 ± 2.67 years, which is almost the same to the study by PR Manjunath et al.[10] where the mean age was 42.07 years (SD 14.5), while a study conducted by Louhibi et al.[11] showed that the mean age was approximately 50 years. MTC was predominantly found in males (65.6%) with a male-to-female ratio of 2:1 in our study, which is almost the same as a study by Mehrotra PK et al.[12] which showed a male-to-female ratio of 1.7:1, while other studies showed a high prevalence in female patients (65%).[11] 68.8% of MTC cases were sporadic in our study and 31.2% percent were familial, a finding consistent with other studies that showed the majority of MTC cases are sporadic (75%–80%), while 20%–25% are hereditary.[13] The mean duration of symptoms was less than 1 year. Out of 10 patients with familial MTC, four were asymptomatic and diagnosed via screening.

disease with pheochromocytoma and RET proto-oncogene mutation.

**Exclusion criteria**

Patients with equivocal results of calcitonin and CEA.
81.2% of patients presented with neck swelling, lymph nodes palpable in 43.8% of the patients, and distant metastasis was present in 25% of the patients, while a study by Finny B et al.[18] showed that 67% of the patients had a definite thyroid swelling and 43% had lymphadenopathy at the time of presentation. Rates of metastasis were highest in bones followed by lungs and liver (12.5%, 9.4% and 3.1%, respectively), while a study by Cherian AJ et al.[15] showed that the most common site of metastasis is lung, followed by bone and liver. The studies conducted by S. Roman et al.[1] and G. Treglia et al.[16] showed that MTC is very aggressive; only about half of the patients have localized disease initially, while 35% had regional lymph node metastases, and 13% have distant metastases, especially to the lung, liver or bones. Other study by M. Roy et al.[17] showed lymph node involvement in 35–50% and distant metastasis in 10–15%. The prevalence of lymph node metastases at diagnosis has varied between 25% and 62% in several other studies.[18,19] Metastasis from MTC occurs via lympho-vascular pathways, spreading to lymph nodes of neck and mediastinum and then further onwards to the lung, liver and bones.[20] Some patients with advanced MTC can develop obstructive symptoms, e.g., dysphagia, due to local growth, while those with distant metastasis can have flushing and diarrhoea due to high levels of calcitonin.[21] In our study, local symptoms, i.e., hoarseness, dyspnoea and vocal cord paralysis, were present in five patients (15.5%), while systemic symptoms, i.e., diarrhoea, were present in two patients (6.2%).

FNAC sensitivity was known to be 63% vs. 98% for serum calcitonin measurement,[22] and definitive diagnosis may only be made after surgery via histopathology.[23] In our study, FNAC detected MTC in 12 (37.5%) patients.

Histologically, the mean tumour size was 7.62 ± 3.64 cm with 8 (25%) patients showing distant metastasis. Lymph node metastasis was present in 18 (56.3%) of the patients. 50% of carcinomas in our study were unifocal, followed by bifocal (21.8%) and multifocal (9.4%).

An elevated level of serum calcitonin is a highly sensitive marker for post-surgery follow-up of MTC, but it is not especially specific.[24] In advanced tumours, which may be dedifferentiated by decreased calcitonin production, CEA may be a more valuable tumour marker.[25] Median pre-surgery calcitonin was 5756 pg/ml (0.0–18.2) that decreased to 29.3 pg/ml post-surgery. Median pre-surgery CEA level was 246.5 ng/ml (0–10) that decreased to 6.39 ng/ml post-surgery.

Hyperparathyroidism was found in two patients, while pheochromocytoma was found in one patient only. Two patients were positive for RET gene mutations. In our study, it was not possible to screen all the patients, as would have been desirable.[26,27] The universal treatment of MTC is total thyroidectomy with central lymph node dissection. A number of studies have reported that survival of MTC patients is dependent upon the adequacy of the initial surgical intervention.[28,29] In our study, total thyroidectomy was performed in 26 (81.2%) of the patients, while in other study 92.6% of patients had total thyroidectomy.[12] One patient had subtotal thyroidectomy followed by completion thyroidectomy as initial FNAC was Bethesda category III. Surgery was not performed in five patients due to distant metastasis or palliative intent. Systemic chemotherapy and external radiotherapy are of limited efficacy in MTC.[30] This is consistent with treatment of patients in our study, in which chemotherapy was given to only one patient, while XRT was performed in two patients.

**CONCLUSION**

Medullary thyroid carcinoma usually presents in the fourth decade of life with male predominance and mostly sporadic occurrence. Total thyroidectomy with subsequent serial calcitonin and CEA levels thereafter are the mainstay of treatment and follow-up.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: Demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107:2134-42.
2. Raue F, Frank-Raue K. Epidemiology and clinical presentation of medullary thyroid carcinoma. Recent Results Cancer Res 2015;204:61-90.
3. Ito T, Shirahana S, Ogura K, Yamamoto S, Takami H. The RET gene in multiple endocrine neoplasia type 2 (MEN 2). Nihon Rinsho 2004;62:883-8.
4. Stepanas AV, Samaan NA, Hill CS Jr, Hickey RC. Medullary thyroid carcinoma. Importance of serial serum calcitonin measurement. Cancer 1979;43:825-37.
5. Kebebew E, Iuarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000;88:1139-48.
6. Barbet J, Campion L, Kraeber-Bodéré F, Chatal JF, GTE Study Group. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005;90:6077-84.
7. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid 2009;19:565-612.
8. Raue F, Frank-Raue K. Long-term follow-up in medullary thyroid carcinoma. Recent Results Cancer Res 2015;204:207-25.
9. Moraitis AG, Martucci VL, Pacak K. Genetics, diagnosis, and management of medullary thyroid carcinoma and pheochromocytoma/paraganglioma. Endocr Pract 2014;20:176-87.
10. Manjunath PR, Vadayath UM, Nair V, Pavithran PV, Bhavani N, Kumar H, et al. Clinical profile of medullary thyroid carcinoma: Audit from a tertiary care center in South India. Indian J Endocrinol Metab 2020;24:355-9.
11. Louhibi L, Marco A, Pinés PJ, Padillo JC, Gómez I, Valero MA, et al. Demographic, clinical, and genetic characteristics of patients with medullary thyroid carcinoma in the past 16 years in Castilla-La Mancha. Endocrinol Nutr 2014;61:398-403.
12. Mehrotra PK, Mishra A, Mishra SK, Agarwal G, Agarwal A, Verma AK. Medullary thyroid cancer: Clinicopathological profile and outcome in a tertiary care center in North India. World J Surg 2011;35:1273-80.
13. Farnon JR, Leighton GS, Dilley WG, Baylin SB, Smallridge RC, Harrison TS, et al. Familial medullary thyroid carcinoma without associated endocrinopathies: A distinct clinical entity. Br J Surg 1986;73:278-81.
14. Finny P, Jacob JJ, Thomas N, Philip J, Rajaratnam S, Oommen R, et al. Medullary thyroid carcinoma: A 20-year experience from a centre in South India. ANZ J Surg 2007;77:130-4.
15. Cherian AJ, Ramakant P, Pai R, Manipadam MT, Elanthenral S, Chandramohan A, et al. Outcome of treatment for medullary thyroid carcinoma—a single centre experience. Indian J Surg Oncol 2018;9:52-8.
16. Treglia G, Rufini V, Salvatori M, Giordano A, Giovanela L. PET imaging in recurrent medullary thyroid carcinoma. Int J Mol Imaging 2012;2012:324686. doi: 10.1155/2012/324686.
17. Roy M, Chen H, Sippel RS. Current understanding and management of medullary thyroid cancer. Oncologist 2013;18:1093-100.
18. Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill JR CS, Hickey RC, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 1984;63:319-42.
19. Jansson S, Hansson G, Salander H, Stenström G, Tisell LE. Prevalence of C-cell hyperplasia and medullary thyroid carcinoma in a consecutive series of pheochromocytoma patients. World J Surg 1984;8:493-500.
20. Machens A, Hinze R, Lauteenschläger C, Thomusch O, Dralle H. Thyroid carcinoma invading the cervicovisceral axis: Routes of invasion and clinical implications. Surgery 2001;129:23-8.
21. Lloyd RV, Osamura RY, Kloppel G, Rosai J. World Health Organization International Agency for Research on Cancer. WHO Classification of Tumours of Endocrine Organs. 4th ed. Lyon: International Agency for Research on Cancer (IARC); 2017.
22. Bugalho MJ, Santos JR, Sobrinho L. Preoperative diagnosis of medullary thyroid carcinoma: Fine needle aspiration cytology as compared with serum calcitonin measurement. J Surg Oncol 2005;91:56-60.
23. Grant EG, Tessler FN, Hoang JK, Langer JE, Beland MD, Berland LL, et al. Thyroid ultrasound reporting lexicon: White paper of the ACR thyroid imaging, reporting and data system (TIRADS) committee. J Am Coll Radiol 2015;12:1272-9.
24. Borget I, De Pouvourville G, Schlumberger M. Calcitonin determination in patients with nodular thyroid disease. J Clin Endocrinol Metab 2007;92:425-7.
25. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 1984;53:278-85.
26. Van Doorn RL, Baudin E, Travagli JP, Schlumberger M, Fromigue J, De Baere T, Baudin E, Dromain C, Leboulleux S, Schlumberger M. Chemoembolization for liver metastases from medullary thyroid carcinoma. J Clin Endocrinol Metab 2006;91:2496-9.